Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2024 09:00 ET | Source: Longeveron

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
June 10, 2024 09:00 ET | Source: Longeveron

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference
June 03, 2024 09:00 ET | Source: Longeveron

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
May 28, 2024 08:05 ET | Source: Longeveron

Longeveron® to Attend BIO International Convention 2024

Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
May 14, 2024 16:05 ET | Source: Longeveron

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
May 10, 2024 16:05 ET | Source: Longeveron

Longeveron Announces Board of Directors Planned Transitions

Longeveron announces planned transitions on its Board of Directors.
May 02, 2024 08:03 ET | Source: Longeveron

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Longeveron to report Q1 2024 financial results on May 14, 2024.
April 25, 2024 16:05 ET | Source: Longeveron

Longeveron to Present at the Planet MicroCap Showcase

Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
April 18, 2024 16:05 ET | Source: Longeveron

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
April 17, 2024 08:00 ET | Source: Longeveron

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.